Shots:
- Amgen has reported topline P-III (OASIZ 301) trial results evaluating dazodalibep vs PBO in adults (n=~621) with Sjögren’s disease with mod. to sev. systemic disease activity (ESSDAI ≥ 5)
- Trial met its 1EP, showing statistically significant & clinically meaningful improvement at Wk. 48, as measured by the ESSDAI, with benefits seen as early as Wk. 4, which were sustained through Wk. 48
- Detailed OASIZ 301 data are expected to be presented at an upcoming meeting, while the P-III (OASIZ 303) study of dazodalibep in mod. to sev. symptomatic Sjögren’s disease is expected to complete in Q4’26
Ref: PRnewswire | Image: Amgen | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
